Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu
Amanda N. Fader,Dana M. Roque,Eric R. Siegel,Natalia Buza,Pei Hui,Osama Abdelghany,Setsuko K. Chambers,Angeles Alvarez Secord,Laura J. Havrilesky,David M. O'Malley,Floor J. Backes,Nicole S. Nevadunsky,Babak Edraki,Dirk Pikaart,William J. Lowery,K. ElSahwi,Paul Celano,Stefania Bellone,Masoud Azodi,Babak Litkouhi,Elena Ratner,Dan-Arin Silasi,Peter E. Schwartz,Alessandro D. Santin +23 more
TLDR
Addition of trastuzumab to carboplatin-paclitaxel was well tolerated and increased progression-free survival, and no unexpected safety signals emerged.Abstract:
PurposeUterine serous carcinoma is a rare, aggressive variant of endometrial cancer. Trastuzumab is a humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (HER2)/neu, a receptor overexpressed in 30% of uterine serous carcinoma. This multicenter, randomized phase II trial compared carboplatin-paclitaxel with and without trastuzumab in patients with advanced or recurrent uterine serous carcinoma who overexpress HER2/neu.MethodsEligible patients had primary stage III or IV or recurrent HER2/neu-positive disease. Participants were randomly assigned to receive carboplatin-paclitaxel (control arm) for six cycles with or without intravenous trastuzumab (experimental arm) until progression or unacceptable toxicity. The primary end point was progression-free survival, which was assessed for differences between treatment arms via one-sided log-rank tests.ResultsFrom August 2011 to March 2017, 61 patients were randomly assigned. Forty progression-free survival–related events occurred a...read more
Citations
More filters
Journal ArticleDOI
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.
Nicole Concin,Xavier Matias-Guiu,Ignace Vergote,David Cibula,Mansoor Raza Mirza,Simone Marnitz,Jonathan A. Ledermann,Tjalling Bosse,Cyrus Chargari,Anna Fagotti,Christina Fotopoulou,Antonio Gonzalez Martin,Sigurd Lax,Domenica Lorusso,Christian Marth,Philippe Morice,Remi A. Nout,Dearbhaile M. O'Donnell,Denis Querleu,Maria Rosaria Raspollini,Jalid Sehouli,Alina Sturdza,Alexandra Taylor,Anneke M. Westermann,Pauline Wimberger,Nicoletta Colombo,François Planchamp,Carien L. Creutzberg +27 more
TL;DR: A European consensus conference on endometrial carcinoma was held in 2014 to produce multi-disciplinary evidence-based guidelines on selected questions as mentioned in this paper, and the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy and Oncologies (ESTRO), and the EPSP jointly decided to update these evidence-base guidelines and to cover new topics in order to improve the quality of care for women with endometrium carcinoma across Europe and worldwide.
Journal ArticleDOI
Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy
Alicia Leon-Castillo,Stephanie M. de Boer,Melanie E Powell,Linda Mileshkin,Helen Mackay,Alexandra Leary,Hans W. Nijman,Hans W. Nijman,Naveena Singh,Pamela M. Pollock,Paul Bessette,Anthony Fyles,Christine Haie-Meder,Vincent T.H.B.M. Smit,Richard J. Edmondson,Hein Putter,Henry C Kitchener,Emma J Crosbie,Marco de Bruyn,Remi A. Nout,Nanda Horeweg,Carien L. Creutzberg,Tjalling Bosse +22 more
TL;DR: Molecular classification has strong prognostic value in high-risk EC, with significantly improved RFS with adjuvant CTRT for p53abn tumors, regardless of histologic type.
Journal ArticleDOI
Current recommendations and recent progress in endometrial cancer.
Rebecca A. Brooks,Rebecca A. Brooks,Gini F. Fleming,Ricardo R. Lastra,Nita K. Lee,John W. Moroney,Christina H. Son,Ken Tatebe,Jennifer L. Veneris +8 more
TL;DR: For the subset of women with microsatellite‐instable, metastatic disease, anti– programmed cell death protein 1 immunotherapy (pembrolizumab) is now approved by the US Food and Drug Administration, and numerous trials are attempting to build on this early success.
Journal ArticleDOI
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial
Stephanie M. de Boer,Melanie E Powell,Linda Mileshkin,Dionyssios Katsaros,Paul Bessette,Christine Haie-Meder,Petronella B. Ottevanger,Jonathan A. Ledermann,Pearly Khaw,Romerai D'Amico,Anthony Fyles,Marie-Helene Baron,Ina M. Jürgenliemk-Schulz,Henry C Kitchener,Hans W. Nijman,G. Wilson,Susan Brooks,Sergio Gribaudo,Diane Provencher,Chantal Hanzen,Roy F.P.M. Kruitwagen,Vincent T.H.B.M. Smit,Naveena Singh,V. Do,Andrea Lissoni,Remi A. Nout,Amanda Feeney,Karen W Verhoeven-Adema,Hein Putter,Carien L. Creutzberg,M McCormack,K Whitmarsh,R Allerton,Deborah Gregory,P. Symonds,Peter Hoskin,M Adusumalli,Anjana Anand,R Wade,Alexandra J. Stewart,W Taylor,L.C.H.W. Lutgens,Harmen Hollema,Elisabeth Pras,An Snyers,GH Westerveld,J.J. Jobsen,Annerie Slot,J.W.M. Mens,Tanja C. Stam,B. van Triest,E. Van der Steen-Banasik,Kaj De Winter,Michael A. Quinn,Ilka Kolodziej,Jan Pyman,Colin D. Johnson,Anne Capp,Roldano Fossati,Alessandro Colombo,Silvestro Carinelli,Annamaria Ferrero,G Artioli,C Davidson,C M McLachlin,Prafull Ghatage,Pvc Rittenberg,Luis Souhami,Gillian Thomas,Pierre Duvillard,Dominique Berton-Rigaud,Nicole Tubiana-Mathieu +71 more
TL;DR: The PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy versus pelvic radiotherapy alone for women with high-risk endometrial cancer and did a post-hoc survival analysis to investigate patterns of recurrence.
Journal ArticleDOI
Clinical actionability of molecular targets in endometrial cancer.
Mary Ellen Urick,Daphne W. Bell +1 more
TL;DR: The overarching molecular features of endometrial cancers are summarized and recent studies assessing the potential clinical utility of specific molecular features for early detection, disease risk stratification and directing targeted therapies are highlighted.
References
More filters
Journal ArticleDOI
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
Elizabeth Eisenhauer,P. Therasse,Jan Bogaerts,Lawrence H. Schwartz,Daniel J. Sargent,Robert Ford,Janet Dancey,S. Arbuck,S. Gwyther,Margaret M. Mooney,Larry Rubinstein,Lalitha K. Shankar,Lori E. Dodd,Robert M. Kaplan,Denis Lacombe,Jaap Verweij +15 more
TL;DR: The revised RECIST includes a new imaging appendix with updated recommendations on the optimal anatomical assessment of lesions, and a section on detection of new lesions, including the interpretation of FDG-PET scan assessment is included.
Journal ArticleDOI
Cancer statistics, 2016
TL;DR: Overall cancer incidence trends are stable in women, but declining by 3.1% per year in men, much of which is because of recent rapid declines in prostate cancer diagnoses, and brain cancer has surpassed leukemia as the leading cause of cancer death among children and adolescents.
Journal ArticleDOI
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Martin M. Oken,Richard H. Creech,Douglass C. Tormey,John Horton,Thomas E. Davis,Eleanor T. McFadden,Paul P. Carbone +6 more
TL;DR: The Eastern Cooperative Oncology Group criteria for toxicity and response are presented to facilitate future reference and to encourage further standardization among those conducting clinical trials.
Journal ArticleDOI
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le,Dung T. Le,Jennifer N. Durham,Jennifer N. Durham,Kellie N. Smith,Hao Wang,Bjarne Bartlett,Bjarne Bartlett,Laveet K. Aulakh,Laveet K. Aulakh,Steve Lu,Steve Lu,Holly Kemberling,Cara Wilt,Brandon Luber,Fay Wong,Fay Wong,Nilofer S. Azad,Agnieszka A. Rucki,Daniel A. Laheru,Ross C. Donehower,Atif Zaheer,George A. Fisher,Todd S. Crocenzi,James J. Lee,Tim F. Greten,Austin G. Duffy,Kristen K. Ciombor,Aleksandra Eyring,Bao H. Lam,Andrew K. Joe,S. Peter Kang,Matthias Holdhoff,Ludmila Danilova,Leslie Cope,Christian F. Meyer,Shibin Zhou,Shibin Zhou,Richard M. Goldberg,Deborah K. Armstrong,Katherine M. Bever,Amanda N. Fader,Janis M. Taube,Franck Housseau,David Spetzler,Nianqing Xiao,Drew M. Pardoll,Nickolas Papadopoulos,Nickolas Papadopoulos,Kenneth W. Kinzler,Kenneth W. Kinzler,James R. Eshleman,Bert Vogelstein,Bert Vogelstein,Robert A. Anders,Robert A. Anders,Luis A. Diaz,Luis A. Diaz +57 more
TL;DR: Evaluating the efficacy of PD-1 blockade in patients with advanced mismatch repair–deficient cancers across 12 different tumor types showed that colorectal cancers with mismatch repair deficiency were sensitive to immune checkpoint blockade with antibodies to programmed death receptor–1 (PD-1).
Journal ArticleDOI
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Antonio C. Wolff,M. Elizabeth H. Hammond,David G. Hicks,Mitch Dowsett,Lisa M. McShane,Kimberly H. Allison,D. C. Allred,John M. S. Bartlett,Michael Bilous,Patrick L. Fitzgibbons,Wedad Hanna,Robert B. Jenkins,Pamela B. Mangu,Soonmyung Paik,Edith A. Perez,Michael F. Press,Patricia A. Spears,Gail H. Vance,Giuseppe Viale,Daniel F. Hayes +19 more
TL;DR: The Update Committee recommends that HER2 status (HER2 negative or positive) be determined in all patients with invasive breast cancer on the basis of one or more HER2 test results (negative, equivocal, or positive).
Related Papers (5)
Integrated genomic characterization of endometrial carcinoma
Gad Getz,Stacey Gabriel,Kristian Cibulskis,Eric S. Lander,Andrey Sivachenko,Carrie Sougnez,Michael S. Lawrence,Cyriac Kandoth,David J. Dooling,Robert S. Fulton,Lucinda Fulton,Joelle Kalicki-Veizer,Michael D. McLellan,Michelle O'Laughlin,Heather Schmidt,Richard K. Wilson,Kai Ye,Ding Li,Adrian Ally,Miruna Balasundaram,Inanc Birol,Yaron S.N. Butterfield,Rebecca Carlsen,Candace Carter,Andy Chu,Eric Chuah,Hye Jung E. Chun,Noreen Dhalla,Ranabir Guin,Carrie Hirst,Robert A. Holt,Steven J.M. Jones,Darlene Lee,Haiyan I. Li,Marco A. Marra,Michael Mayo,Richard A. Moore,Andrew J. Mungall,Patrick Plettner,Jacqueline E. Schein,Payal Sipahimalani,Angela Tam,Richard Varhol,A. Gordon Robertson,Andrew D. Cherniack,Itai Pashtan,Gordon Saksena,Robert C. Onofrio,Steven E. Schumacher,Barbara Tabak,Scott L. Carter,Bryan Hernandez,Jeff Gentry,Helga B. Salvesen,Helga B. Salvesen,Kristin G. Ardlie,Wendy Winckler,Rameen Beroukhim,Rameen Beroukhim,Matthew Meyerson,Angela Hadjipanayis,Semin Lee,Harshad S. Mahadeshwar,Peter J. Park,Alexei Protopopov,Xiaojia Ren,Sahil Seth,Xingzhi Song,Jiabin Tang,Ruibin Xi,Lixing Yang,Zeng Dong,Raju Kucherlapati,Lynda Chin,Lynda Chin,Jianhua Zhang,Jianhua Zhang,J. Todd Auman,Saianand Balu,Tom Bodenheimer,Elizabeth Buda,D. Neil Hayes,Alan P. Hoyle,Stuart R. Jefferys,Corbin D. Jones,Shaowu Meng,Piotr A. Mieczkowski,Lisle E. Mose,Joel S. Parker,Charles M. Perou,Jeff Roach,Shi Yan,Janae V. Simons,Mathew G. Soloway,Donghui Tan,Michael D. Topal,Scot Waring,Junyuan Wu,Katherine A. Hoadley,Stephen B. Baylin,Moiz S. Bootwalla,Phillip H. Lai,Timothy J. Triche,David Van Den Berg,Daniel J. Weisenberger,Peter W. Laird,Hui Shen,Hui Shen,Hui Shen,Juok Cho,Daniel DiCara,Scott Frazer,David I. Heiman,Rui Jing,Pei Lin,Will Mallard,Petar Stojanov,Doug Voet,Hailei Zhang,Lihua Zou,Michael S. Noble,Sheila Reynolds,Ilya Shmulevich,B. Arman Aksoy,Yevgeniy Antipin,Giovanni Ciriello,Gideon Dresdner,Jianjiong Gao,Benjamin Gross,Anders Jacobsen,Marc Ladanyi,Boris Reva,Chris Sander,Rileen Sinha,S. Onur Sumer,Barry S. Taylor,Ethan Cerami,Nils Weinhold,Nikolaus Schultz,Ronglai Shen,Stephen C. Benz,Theodore C. Goldstein,David Haussler,Sam Ng,Christopher Szeto,Joshua M. Stuart,Christopher C. Benz,Christina Yau,Wei Zhang,Matti Annala,Matti Annala,Bradley M. Broom,Tod D. Casasent,Zhenlin Ju,Han Liang,Guoyan Liu,Yiling Lu,Anna K. Unruh,Chris Wakefield,John N. Weinstein,Nianxiang Zhang,Yuexin Liu,Russell Broaddus,Rehan Akbani,Gordon B. Mills,Christopher Adams,Thomas Barr,Aaron D. Black,Jay Bowen,John Deardurff,Jessica Frick,Julie M. Gastier-Foster,Julie M. Gastier-Foster,Thomas Grossman,Hollie A. Harper,Melissa Hart-Kothari,Carmen Helsel,Aaron Hobensack,Harkness Kuck,Kelley Kneile,Kristen M. Leraas,Tara M. Lichtenberg,Cynthia McAllister,Robert E. Pyatt,Nilsa C. Ramirez,Nilsa C. Ramirez,Teresa R. Tabler,Nathan Vanhoose,Peter White,Lisa Wise,Erik Zmuda,Nandita Barnabas,Charlenia Berry-Green,Victoria Blanc,Lori Boice,Michael Button,Adam M. Farkas,Alexander A. Green,Jean MacKenzie,Dana Nicholson,Steve E. Kalloger,C. Blake Gilks,Beth Y. Karlan,Jenny Lester,Sandra Orsulic,Mark E. Borowsky,Mark G. Cadungog,Christine Czerwinski,Lori Huelsenbeck-Dill,Mary Iacocca,Nicholas J. Petrelli,Brenda Rabeno,Gary Witkin,Elena Nemirovich-Danchenko,Olga Potapova,D L Rotin,Andrew Berchuck,Michael J. Birrer,P.J. DiSaia,Laura Monovich,Erin Curley,Johanna Gardner,David Mallery,Robert Penny,Sean C. Dowdy,Boris Winterhoff,Linda Dao,Bobbie S. Gostout,Alexandra Meuter,Attila Teoman,Fanny Dao,Narciso Olvera,Faina Bogomolniy,Karuna Garg,Robert A. Soslow,Mikhail Abramov,John M. S. Bartlett,Sugy Kodeeswaran,Jeremy Parfitt,Fedor Moiseenko,Blaise A. Clarke,Marc T. Goodman,Michael E. Carney,Rayna K. Matsuno,Jennifer O. Fisher,Mei Huang,W. Kimryn Rathmell,Leigh B. Thorne,Linda Van Le,Rajiv Dhir,Robert Edwards,Esther Elishaev,Kristin K. Zorn,Paul J. Goodfellow,Paul J. Goodfellow,Paul J. Goodfellow,David G. Mutch,Ari B. Kahn,Daphne W. Bell,Pamela M. Pollock,Chen Wang,David A. Wheeler,Eve Shinbrot,Li Ding,Elaine R. Mardis,Brenda Ayala,Anna L. Chu,Mark A. Jensen,Prachi Kothiyal,Todd Pihl,Joan Pontius,David Pot,Eric E. Snyder,Deepak Srinivasan,Kenna R. Mills Shaw,Margi Sheth,Tanja Davidsen,Greg Eley,Martin L. Ferguson,Liming Yang,Mark S. Guyer,Bradley A. Ozenberger,Heidi J. Sofia,Douglas A. Levine +283 more
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
Stephanie M. de Boer,Melanie E Powell,Linda Mileshkin,Dionyssios Katsaros,Paul Bessette,Christine Haie-Meder,Petronella B. Ottevanger,Jonathan A. Ledermann,Pearly Khaw,Alessandro Colombo,Anthony Fyles,Marie Helene Baron,Ina M. Jürgenliemk-Schulz,Henry C Kitchener,Hans W. Nijman,G. Wilson,Susan Brooks,Silvestro Carinelli,Diane Provencher,Chantal Hanzen,Ludy C.H.W. Lutgens,Vincent T.H.B.M. Smit,Naveena Singh,V. Do,Romerai D'Amico,Remi A. Nout,Amanda Feeney,Karen W Verhoeven-Adema,Hein Putter,Carien L. Creutzberg,Mary McCormack,Karen Whitmarsh,Rozenn Allerton,Deborah Gregory,P. Symonds,Peter Hoskin,Madhavi Adusumalli,Anjana Anand,Robert Wade,Alexandra J. Stewart,Wendy Taylor,Roy F.P.M. Kruitwagen,Harry Hollema,Elizabeth Pras,An Snyers,Lukas J.A. Stalpers,Jan J. Jobsen,Annerie Slot,Jan Willem M. Mens,Tanja C. Stam,Baukelien Van Triest,Elzbieta M. Van der Steen Banasik,Karin A.J. De Winter,Michael A. Quinn,Ilka Kolodziej,Jan Pyman,Carol Johnson,Anne Capp,Roldano Fossati,Sergio Gribaudo,Andrea Lissoni,Annamaria Ferrero,Grazia Artioli,Cathy Davidson,C. Meg McLachlin,Prafull Ghatage,Paula V.C. Rittenberg,Luis Souhami,Gillian Thomas,Pierre Duvillard,Dominique Berton-Rigaud,Nicole Tubiana-Mathieu +71 more